Inflammatory breast carcinoma (IBC) is a rare form of breast cancer characterized by a rapid onset of diffuse skin erythema, edema, induration, and warmth of the breast. Biologically, IBC is usually hormone receptor (HR) negative and experience an overexpression of human epidermal growth factor receptor 2 (HER2), with a high mitotic index (MIB‐1 \> 20%). Median overall survival is poor.[1](#tbj13606-bib-0001){ref-type="ref"}

Lapatinib is an oral drug that inhibits the tyrosine kinases of HER2 and epidermal growth factor receptor type 1 (EGFR) and has demonstrated clinical activity in trastuzumab‐refractory states.[2](#tbj13606-bib-0002){ref-type="ref"} Lapatinib has also shown clinical activity in IBC, but evidence in this field is scarce.[3](#tbj13606-bib-0003){ref-type="ref"}, [4](#tbj13606-bib-0004){ref-type="ref"}, [5](#tbj13606-bib-0005){ref-type="ref"}, [6](#tbj13606-bib-0006){ref-type="ref"}, [7](#tbj13606-bib-0007){ref-type="ref"}, [8](#tbj13606-bib-0008){ref-type="ref"}, [9](#tbj13606-bib-0009){ref-type="ref"}

We present the case of an approximately ten‐year maintained complete response using lapatinib and capecitabine to treat an IBC early relapse after trastuzumab treatment.

A 34‐year‐old woman was diagnosed with multifocal invasive ductal carcinoma of the right breast (grade III). The immunohistochemical study showed the lesion tested negative for HR and positive for HER2 protein expression (3+). MIB‐1 expression was high, more than 25%, and a strong nuclear P53 expression was established. The patient was diagnosed with locally advanced breast cancer (cT2cN1M0).

In April 2007, neo‐adjuvant chemotherapy was initiated using doxorubicin plus cyclophosphamide during four cycles, followed by docetaxel administered concurrently with trastuzumab for an additional four cycles. Complete radiological and clinical responses were achieved. A breast‐conserving surgery was performed on the right breast in November 2007.

Final pathological results were consistent with multifocal invasive ductal carcinoma. The main focal lesion was 2.2 cm with a high grade (III), intraductal component in the main tumor was between 25% and 75%, and lymphovascular invasion was evident. Histological response was classified as no response or minimal response (Miller‐Payne grade 1). Clear margins were obtained, and no affected lymph nodes were noted among the 16 that were removed.

Trastuzumab was given every three weeks for a complete year. During this time, the patient also received radiotherapy by irradiation of the right breast volume and the regional lymph node area, as well as brachytherapy.

In January 2009, six months after completing trastuzumab therapy, the patient presented a local recurrence in the right breast. The recurrence was diagnosed as inflammatory carcinoma (dermal lymphatic invasion) with infiltrating ductal carcinoma histology (grade III, HR negative, HER2 positive, p53 positive, MIB‐1 \> 40%). Carboplatin, paclitaxel, and trastuzumab combination therapy was initiated. After four cycles, partial clinical response was achieved and a right mastectomy was performed. Pathological results indicated multifocal infiltrating ductal carcinoma and were consistent with the previous biopsy.

In September 2009, one month after surgery, recurrence of carcinoma was identified both at the base of the mastectomy and in contralateral lymph nodes, but no distant metastases were found in extensive studies.

First‐line treatment for advanced and trastuzumab‐resistant disease using capecitabine (1000 mg/m^2^ PO BID on days 1‐14) plus lapatinib (1250 mg PO on days 1‐21) every three weeks was proposed. After six cycles, lesion in left lymph node and skin lesions on the base of the mastectomy scar disappeared, achieving a complete response. Therefore, treatment was continued until present time, May 2019, for a total of 144 cycles of treatment. The patient achieved excellent tolerance, except a grade II hand‐foot syndrome at various occasions that required a capecitabine dose reduction and a delay in its administration (every 28 days). After approximately 10 years of treatment, no evidence of regional or systemic disease has been observed and the patient has a good quality of life.

Compared with capecitabine alone, lapatinib in combination with capecitabine increases time to progression (TTP) in patients who have progressed after/on trastuzumab, anthracyclines or taxanes. In one study, the median TTP was eight months in the combination arm and four months in the capecitabine arm (HR 0.49; *P* \< .001). However, the evidence supporting the efficacy of lapatinib or its combinations in IBC is scarce.[2](#tbj13606-bib-0002){ref-type="ref"}

Lapatinib has shown remarkable activity in IBC in two phase II trials. The response rates are varied, which range from 39% to no complete response, in one study, and from 47% to a single complete response, in the other. Median progression‐free survival in both studies was similar, 15 and 16 weeks, respectively.[3](#tbj13606-bib-0003){ref-type="ref"}, [4](#tbj13606-bib-0004){ref-type="ref"} Lapatinib and chemotherapy combination has also been studied in neo‐adjuvant setting in IBC. In a phase II trial, treatment‐naive patients received lapatinib for 14 days and then lapatinib with weekly paclitaxel for 12 weeks. In HER2 positive patients, combined clinical response rate (clinically evaluable skin disease and RECIST criteria) was 78% and pathological response rate was 18% (Table [1](#tbj13606-tbl-0001){ref-type="table"}).[5](#tbj13606-bib-0005){ref-type="ref"}

###### 

Clinical trials of lapatinib in inflammatory breast cancer and its comparison with pivotal trial of lapatinib and capecitabine in HER2 positive advanced breast cancer

  Journal                   Pub    Phase   Setting       N     Stage IIIB‐C   Stage IV   Anthrac   Trast M         Lapatinib dose           Combination treatment       ORR   CBR   CR    PR    SD       PFS      OS
  ------------------------- ------ ------- ------------- ----- -------------- ---------- --------- --------------- ------------------------ --------------------------- ----- ----- ----- ----- -------- -------- --------
  NEJM                      2006   III     R/R LA or M   163   4%             96%        97%       96%             1250 mg daily            Capecitabine 2000 mg/m^2^   22%   27%   1%    21%   5%       8,4 m    x
  Lancet Oncol              2009   II      R/R LA or M   126   22%            78%        84%       75%             1500 mg daily            No                          39%   65%   0%    39%   26%      14,6 w   11,2 m
  Breast Cancer Res Treat   2013   II      R/R LA or M                                                                                                                                                             
                                           Coh 1 (38)    16%   84%            83%        55%       1500 mg daily   No                       29%                         66%   3%    26%   37%   16,1 w   14,7 m   
                                           Coh 1 (38)    16%   84%            83%        58%       1500 mg daily   Pazopanib 800 mg daily   45%                         61%   11%   34%   16%   14,3 w   16,2 m   
                                           Coh 2 (36)    19%   75%            85%        50%       1500 mg daily   No                       47%                         80%   3%    44%   33%   16 w     15,9 m   
                                           Coh 2 (38)    34%   63%            85%        50%       1000 mg daily   Pazopanib 400 mg daily   58%                         84%   0%    58%   26%   16 w     x        
  J Clin Oncol              2010   II      Neoadjuvant                                                                                                                                                             
                                           Coh A (42)    83%   17%            0%         0%        1500 mg daily   Weekly paclitaxel        79%                         86%   0%    79%   7%             x        

Journal, abbreviated title of journal; Pub year, year of publication of the article; Phase, clinical trial phase; Setting, R/R LA or M (relapsed/refractory locally advanced or metastatic breast cancer); N, number of patients included (Coh: Cohort \[only cohorts containing monotherapy or combination lapatinib treatment have been included\]); Anthrac, previous treatment with anthracyclines; Trast M, previous treatment with trastuzumab for metastatic disease; ORR, objective response rate (complete response rate and partial response rate: combining of clinically evaluable skin disease criteria and RECIST criteria, if applicable); CBR, clinical benefit rate (ORR and stable disease rate); CR, complete response rate; PR, partial response rate; SD, stable disease rate; PFS, progression‐free survival; OS, overall survival; W, weeks; M, months; X, data not available.

John Wiley & Sons, Ltd

Lapatinib and capecitabine for IBC were used in two case reports. In one of the case reports, a heavily pretreated patient had a local progression after 6 months of receiving 1250 mg per day of lapatinib and 1000 mg of capecitabine per square meter days 1‐14. Metronomic capecitabine was then started, 500 mg thrice daily, with the same dose of lapatinib, and disease control was achieved for 20 additional weeks.[6](#tbj13606-bib-0006){ref-type="ref"} In another case, double blockade with lapatinib and trastuzumab has been reported to be as effective as maintenance therapy in stage IV IBC, after initial treatment with chemotherapy and trastuzumab combination. The patient achieved stable metastatic disease during four years, and she is still in treatment.[7](#tbj13606-bib-0007){ref-type="ref"}

Some studies have addressed the issue of long‐term survival with anti‐HER2 therapy, although most were based on trastuzumab (Table [2](#tbj13606-tbl-0002){ref-type="table"}), not lapatinib, and none was specifically directed at IBC.

###### 

Factors associated with long‐term survival with trastuzumab anti‐HER2 therapy for metastatic disease

  First author (Journal)                             Pub year   Long‐term survival‐associated factors
  -------------------------------------------------- ---------- ---------------------------------------
  Gamez‐Pozo A (PLoS One)                            2014       No trastuzumab as adjuvant therapy
  No alterations in PI3K‐mTOR pathway                           
  Yardley DA (Br J Cancer)                           2014       HR positivity
  Mtx to bone or bone + breast or node/local sites              
  First‐line trastuzumab plus taxane use                        
  Harano K (Breast Cancer Res Treat)                 2016       HR positivity
  Low burden of disease                                         
  Mtx to bone and soft tissues                                  
  Resection of the mtx site and primary tumour                  
  Murthy P (Breast Cancer Res Treat)                 2016       Younger age at diagnosis
  Lower stage                                                   
  HR positivity                                                 
  Only one organ involved at diagnosis                          
  Omarini C (Cancer Biol Ther)                       2018       No central nervous system spread
  Low burden of disease                                         
  No trastuzumab as adjuvant therapy                            

Journal, abbreviated title of journal; Pub year, year of publication of the article; HR, hormone receptor; Mtx, metastasis.

John Wiley & Sons, Ltd

About toxicity, our patient had limitant dose toxicity. In some studies, lapatinib‐associated mucocutaneous toxicities have been proposed as predictors of improved progression‐free survival in HER2‐positive IBC patients, but we do not know the repercussion of this aspect yet.[8](#tbj13606-bib-0008){ref-type="ref"}

Some difficulties stand out in the management of IBC, particularly the definition of it which is usually based on clinical criteria, dermal lymphatic invasion is not mandatory, as well as in defining response, since a clinical response may or may not be accompanied by a radiological response at the same time.[9](#tbj13606-bib-0009){ref-type="ref"}

The improvement of response and survival outcomes in IBC involves investigating new pathways and molecular targets, as well as identifying biomarkers that determine which patient will benefit of a drug already studied like lapatinib.[10](#tbj13606-bib-0010){ref-type="ref"}
